Genmab axes development of AXL-targeting cancer drug enapotamab vedotinGenmab has axed development of its pipeline cancer drug enapotamab vedotin after it failed to show enough activity Share XGenmab axes development of AXL-targeting cancer drug enapotamab vedotinhttps://pharmaphorum.com/news/genmab-axes-development-axl-targeting-cancer-drug-enapotamab-vedotin/
Novartis set to overcome $14 billion patent cliff say analystsNovartis’ pipeline is strong enough to overcome a $14 billion patent cliff as blockbuster drugs face generic competition Share XNovartis set to overcome $14 billion patent cliff say analystshttps://pharmaphorum.com/news/novartis-set-to-overcome-14-billion-patent-cliff-analyst/
AstraZeneca ‘probably couldn’t run Gilead any better:’ analystAstraZeneca and Gilead are both staying tight-lipped over rumoured merger talks, but the consensus among analysts seems to Share XAstraZeneca ‘probably couldn’t run Gilead any better:’ analysthttps://pharmaphorum.com/news/astrazeneca-probably-couldnt-run-gilead-any-better-analyst/
AZ reportedly mulls biggest-ever pharma merger with GileadAlmost exactly six years ago AstraZeneca managed to convince investors to reject a takeover bid from Pfizer – Share XAZ reportedly mulls biggest-ever pharma merger with Gileadhttps://pharmaphorum.com/news/az-reportedly-mulls-biggest-ever-pharma-merger-with-gilead/
NodThera raises $55m in Series B round to trial inflammatory disease drugsThe Anglo-US biotech NodThera has raised $55 million in a second financing round as it prepares its inflammatory Share XNodThera raises $55m in Series B round to trial inflammatory disease drugshttps://pharmaphorum.com/news/nodthera-raises/
Failed trial puts future of UCB’s epilepsy drug padsevonil in doubtShares in UCB slid this morning after the Belgian company announced its refractory epilepsy drug candidate padsevonil had Share XFailed trial puts future of UCB’s epilepsy drug padsevonil in doubthttps://pharmaphorum.com/news/failed-trial-puts-future-of-ucbs-epilepsy-drug-padsevonil-in-doubt/
Novartis says mid-stage pipeline is setting up strong growth spurtNovartis kicked off its R&D update in London this morning by pledging to bring at least 10 drugs Share XNovartis says mid-stage pipeline is setting up strong growth spurthttps://pharmaphorum.com/news/novartis-says-mid-stage-pipeline-is-setting-up-strong-growth-spurt/
Boehringer pins hopes on novel psoriasis drugImmune disorder drug is highlight of pipeline Share XBoehringer pins hopes on novel psoriasis drughttps://pharmaphorum.com/news/boehringer-pins-hopes-on-novel-psoriasis-drug/
Infographic: Solving the challenges of immuno-oncology trialsThe booming interest in new targeted therapies represents a changing of the guard in cancer treatment, from the Share XInfographic: Solving the challenges of immuno-oncology trialshttps://pharmaphorum.com/views-and-analysis/overcoming-challenges-immuno-oncology-trials-60-seconds/